Smith J A, Middleton R G
J Urol. 1985 Apr;133(4):617-9. doi: 10.1016/s0022-5347(17)49112-9.
We divided 73 cases of pelvic nodal metastases from prostatic cancer into subgroups based upon the volume and extent of nodal disease. Of the patients with gross nodal disease 15 per cent survived 5 years without progression compared to 27 per cent of those with microscopic involvement of more than 1 node and 44 per cent with a single positive node. On the other hand, 52 per cent of the patients with gross disease died of prostatic cancer within 5 years compared to 37 per cent of those with multiple microscopic nodes and 28 per cent with a single node. Although other variables also influence prognosis, the differences in survival demonstrable within these subgroups may have important implications regarding selection of therapy and interpretation of treatment results.
我们根据前列腺癌盆腔淋巴结转移的体积和范围，将73例患者分为不同亚组。在有明显淋巴结转移的患者中，15%存活5年且无病情进展，而有超过1个淋巴结微小转移的患者这一比例为27%，仅有1个阳性淋巴结的患者为44%。另一方面，有明显转移的患者中，52%在5年内死于前列腺癌，而有多个微小转移淋巴结的患者这一比例为37%，仅有1个转移淋巴结的患者为28%。尽管其他变量也会影响预后，但这些亚组中明显的生存差异可能对治疗选择和治疗结果的解读具有重要意义。
